• Heartbeam outlined plans to launch its FDA 510(k)-cleared HeartBeam System for arrhythmia assessment, positioning it as a cable-free synthesized 12-lead ECG platform.
• Regulatory milestones cited include FDA 510(k) clearance in 12/2024 for the system, followed by 12/2025 clearance for its 12-lead ECG synthesis algorithm.
• Commercial strategy centers on a limited rollout through concierge and preventive cardiology practices, targeting New York, Dallas, South Florida, Southern California.
• Business model targets 70%+ recurring gross margins, 3-5 month payback on year-one upfront costs, cash-flow break-even at about 30,000 patients.
• Market sizing framed as 50 million-plus at-risk patients and a $40 billion platform opportunity, with an initial 1.5 million-patient concierge segment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.